We have located links that may give you full text access.
Diagnosis and treatment of prolactinomas.
Expert Review of Endocrinology & Metabolism 2009 March
Prolactinomas account for approximately 40% of all pituitary adenomas. Hyperprolactinemia causes hypogonadism, infertility and galactorrhea. Macroprolactinomas may cause signs of local expansion, such as headache, visual field defects and paresis of oculomotor nerves during suprasellar and parasellar extensions. Compression of healthy pituitary tissue together with the blockade of the flow of hypothalamic released hormones to the pituitary by macroprolactinomas results in the development of hypopituitarism. The aim of treatment is restoration of hypogonadism and fertility in the microprolactinoma patients, as well as tumor shrinkage in macroprolactinoma patients. Primary therapy for prolactinomas is pharmacological treatment with dopamine agonists (DAs). However, surgical or radiation treatment is recommended for prolactinoma patients resistant or intolerant to DAs. In patients with long-term normoprolactinemia and significant tumor shrinkage, a trial of tapering and discontinuation of medical therapy is possible. After discontinuation of DAs, a long-term follow-up is necessary. In cases of recurrence displaying hyperprolactinemia and tumor enlargement, treatment must be resumed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app